Journal of Korean Medicine for Obesity Research (한방비만학회지)

The Society of Korean Medicine for obesity Research (한방비만학회)
권호 표지
DOI QR코드

DOI QR Code

Gamitaeeumjowee-tang for Patients with Class II or III Obesity: A Retrospective Chart Review

중고도비만 환자에 대한 가미태음조위탕의 활용: 후향적 차트 리뷰

  • Yoo-Been Lee (Nubebe Korean Medical Clinic Incheon Center) ;
  • A-Reum Lee (Nubebe Korean Medical Clinic Bucheon Center) ;
  • Min-Ju Son (Nubebe Korean Medical Clinic Bucheon Center) ;
  • Si-Hyeon An (Nubebe Korean Medical Clinic Bucheon Center) ;
  • Ji-Yeon Han (Nubebe Korean Medical Clinic Bucheon Center)
  • 이유빈 (누베베 한의원 인천점) ;
  • 이아름 (누베베 한의원 부천점) ;
  • 손민주 (누베베 한의원 부천점) ;
  • 안시현 (누베베 한의원 부천점) ;
  • 한지연 (누베베 한의원 부천점)
  • Received : 2024.04.06
  • Accepted : 2024.05.27
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The purpose of this study was to evaluate changes in body weight and blood pressure and also analyze adverse events after weight loss program using Gamitaeeumjowee-tang in patients with class II or III obesity, considering for metabolic and bariatric surgery. Methods: A retrospective chart review was conducted on class III obesity or class II obesity patients with comorbidities, who participated in 24-week weight loss program using Gamitaeeumjowee-tang (n=54). The analysis included changes in body weight, body mass index, fat mass, skeletal muscle mass, waist-hip ratio and blood pressure before and after the program. And also calculated the proportion of patients who lost more than 5%, 10%, and 15% of their initial weight. Adverse events were assessed by causality, severity and system-organ classes. Results: After the weight loss program, body weight decreased 12.21±6.43 kg (12.77%), and BMI decreased 4.61±2.25 kg/m2 (12.75%) on average (P<0.05). The 90.7% of the subjects lost more than 5% of their weight, 68.5% lost more than 10%, and 35.1% lost more than 15% of their weight. Blood pressure significantly decreased 11.04±14.53 mmHg in systolic and 7.28±11.89 mmHg in diastolic on average (P<0.05). The 97% of adverse events were mild, and 75% were evaluated as 'unlikely' in the causality evaluation. Conclusions: The results of this study, the weight loss program using Gamitaeeumjowee-tang showed significant weight loss and blood pressure reduction in patients with class III obesity or class II obesity with comorbidities, without serious adverse events. Well-designed clinical studies are recommended for the future.

Keywords

References

  1. Ruban A, Stoenchev K, Ashrafian H, Teare J. Current treatments for obesity. Clin Med (Lond). 2019 ; 19(3) : 205-12.
  2. Korean Society for the Study of Obesity. Clinical practice guidelines for obesity. 8th ed. Seoul : Korean Society for the Study of Obesity. 2022 : 14-9, 131-43.
  3. Nam GE. Current status and epidemiology of adult obesity in Korea. J Korean Med Assoc. 2022 ; 6 5(7) : 394-9.
  4. Yang YS, Han BD, Han K, Jung JH, Son JW; Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity. Obesity fact sheet in Korea, 2021: trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr. 2022 ; 31(2) : 169-77.
  5. Park E. The obesity and the metabolic syndrome among Korean adults: based on national representative survey. Korean J Health Promot. 2020 ; 20(4) : 144-50.
  6. Park JH, Park DJ, Kim H, Park H, Lee B, Nam H, et al. Twelve-year trajectory of disease burden and mortality by obesity level in Korea: analysis of the National Health Insurance Service database. Obes Surg. 2023 ; 33(1) : 105-16.
  7. Korean Society for the Study of Obesity. 2022 Obesity fact sheet. Seoul : Korean Society for the Study of Obesity. 2022 : 8-13.
  8. Lee YJ. Assessing quality of life for morbidly obese patient. J Metab Bariatr Surg. 2012 ; 1(2) : 93-7.
  9. Rhee EJ. Current status of obesity treatment in Korea: based on the 2020 Korean Society for the Study of Obesity guidelines for obesity management. J Korean Med Assoc. 2022 ; 65(7) : 388-92.
  10. Lee DY, Lee CM. Surgical treatment for obesity. J Korean Med Assoc. 2022 ; 65(7) : 417-22.
  11. Park H, Huh Y, Kim SH, Yoo MW, Ko CS, Park HS. Longitudinal changes of body weight according to sex.age and metabolic parameters in Korean morbid obese patients after sleeve gastrectomy: 12-month retrospective cohort study. Korean J Fam Pract. 2022 ; 12(3) : 185-92.
  12. Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020 ; 324(9) : 879-87.
  13. Kim S, Han K, Kwon O, Lee W, Yoon C, Lee JH. Effect of Korean medicine treatment including Korean medicine counselling on weight loss in patients with morbid obesity: a retrospective chart review. J Korean Med Obes Res. 2021 ; 21(1) : 22-31.
  14. Han YJ, Cha J. Herbal medicine with diet control and exercise for class III obesity: a case report. J Korean Med Obes Res. 2021 ; 21(2) : 105-11.
  15. Han HJ, Kim HJ, Park EY, Jang JA, An TH, Seo HS, et al. The effect of oriental obesity therapy on morbid obese patient with type 2 diabetes: two cases report. J Korean Med Obes Res. 2010 ; 10(1) : 57-63.
  16. Kang EY, Park YB, Kim MY, Park YJ. A study on factors associated with weight loss by 'Gamitaeeumjowee-tang'. J Korean Med Obes Res. 2017 ; 17(2) : 68-76.
  17. Kim SJ, Seo YH, Lee HS, Chang HK, Cho JH, Kim KW, et al. Research trends of herbal medicines for obesity: mainly since 2015 to 2019. J Korean Med Rehabil. 2020 ; 30(4) : 89-103.
  18. Yoon NR, Yoo YJ, Kim MJ, Kim SY, Lim YW, Lim HH, et al. Analysis of adverse events in weight loss program in combination with 'Gamitaeeumjowee-tang' and low-calorie diet. J Korean Med Obes Res. 2018 ; 18(1) : 1-9.
  19. Park MJ, Kim E, Ok JM, Choi KH, Lim YW. Gamitaeeumjowee-tang for weight loss in overweight and obese women with polycystic ovary syndrome: a retrospective chart review. J Korean Med Obes Res. 2022 ; 22(2) : 136-46.
  20. Lee AR, Lee DY, Kim MJ, Lee HS, Choi KH, Kim SY, et al. Gamitaeeumjowee-tang for weight loss in diabetic patients: a retrospective chart review. J Korean Med. 2021 ; 42(1) : 46-58.
  21. Kim MJ, Won BY, Kim HJ, Choi KH. Clinical application of Gamitaeeumjowee-tang for overweight or obese hypothyroidism patients: a retrospective chart review. J Korean Med Obes Res. 2023 ; 23(2) : 78-85.
  22. Lee MK, Cheng BW, Che CT, Hsieh DP. Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation. Toxicol Sci. 2000 ; 56(2) : 424-30.
  23. Jang IS, Yang CS, Hwang EH. The need for clinical practice guidelines in usage of Mahuang in weight loss. J Korean Med Obes Res. 2007 ; 7(1) : 23-9.
  24. Jo GW, Ok JM, Kim SY, Lim YW. Review on the efficacy and safety of Mahuang and ephedrine in the treatment of obesity-focused on RCT. J Korean Med. 2017 ; 38(3) : 170-84.
  25. Park S, Park MJ, Kim E, Lim YW. Review on predictors of weight loss in moderate to severe obesity treatment. J Korean Med Obes Res. 2023 ; 23(2) : 98-111.
  26. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015 ; 373(1) : 11-22.
  27. Wharton S, Haase CL, Kamran E, Liu A, Mancini J, Neish D, et al. Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada. Obes Sci Pract. 2020 ; 6(4) : 439-44.
  28. Nam SH, Kim SY, Lim YW, Park YB. Review on predictors of weight loss in obesity treatment. J Korean Med Obes Res. 2018 ; 18(2) : 115-27.
  29. Han JY, Park YJ. Analysis of factors influencing obesity treatment according to initial condition and compliance with medication. J Korean Med Obes Res. 2019 ; 19(1) : 31-41.
  30. Harsha DW, Bray GA. Weight loss and blood pressure control (Pro). Hypertension. 2008 ; 51(6) : 1420-5.
  31. Brockow K, Przybilla B, Aberer W, Bircher AJ, Brehler R, Dickel H, et al. Guideline for the diagnosis of drug hypersensitivity reactions. Allergo J Int. 2015 ; 24(3) : 94-105.